Loading
A phase 3 trial of Eribulin, Vinorelbine, Gemcitabine and Capecitabine in advanced solid tumours, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01) is a phase 3 interventional study registered as NCT06343948 by Sichuan Baili Pharmaceutical Co., Ltd., with 383 participants enrolled, started 2024-04-24 and due to reach its primary completion in 2026-08. Interventions recorded: BL-B01D1, Eribulin, Vinorelbine, Gemcitabine and Capecitabine.
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
Shares Eribulin, SystImmune / Sichuan Biokin, Capecitabine, Gemcitabine and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Eribulin, Capecitabine, Gemcitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Metastatic cancer (cancer that has spread) and the tag pipeline.